Sequential instillation therapy with mitomycin C and adriamycin for superficial bladder tumors

Area of Science:

• Urology
• Oncology
• Pharmacology

Background:

• Superficial bladder tumors (Ta, Tl, Tis) represent a significant clinical challenge.
• Previous treatments for these tumors have varied efficacy and recurrence rates.

Purpose of the Study:

• To evaluate the efficacy and toxicity of sequential intravesical mitomycin C (MMC) and adriamycin (ADM) for superficial bladder tumors.
• To compare the effectiveness of prophylactic intermittent MMC instillation versus daily oral 5-fluorouracil (5-FU) in preventing tumor recurrence.

Main Methods:

• Eighty-four patients with superficial bladder tumors received weekly sequential intravesical MMC (20 mg) and ADM (40 mg) for 5 weeks.
• Patients achieving complete response were randomized to receive either intermittent MMC instillation or daily oral 5-FU as prophylactic treatment.
• Response rates, tumor characteristics, toxicity, and recurrence rates were analyzed.

Main Results:

• An overall response rate of 68% was observed, with 54% achieving complete response (CR) and 14% partial response (PR).
• Patients with fewer than five tumors or tumors smaller than 1 cm had significantly better response rates.
• The most common toxicity was cystitis (74%), leading to discontinuation in some cases; no systemic toxicity was noted.
• Preliminary analysis indicated intermittent MMC instillation was more effective than oral 5-FU in reducing recurrence for up to 2 years.

Conclusions:

• Sequential intravesical MMC and ADM is an effective treatment for superficial bladder tumors, particularly for patients with fewer or smaller tumors.
• While cystitis is a common side effect, the treatment is generally well-tolerated systemically.
• Intermittent intravesical MMC appears to be a superior prophylactic strategy compared to oral 5-FU for reducing long-term recurrence.